NEW YORK, NY, USA I September 04, 2019 I Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the initiation of a Phase 3 registrational trial for AT-001, a novel, potent and selective aldose reductase inhibitor (ARI), in Diabetic Cardiomyopathy (DbCM). The study, called ARISE-HF, will investigate AT-001’s ability to improve or prevent the decline of functional capacity in patients with DbCM at high risk of progression to overt heart failure.
Aldose reductase (AR) activity has been implicated as a strong contributing factor to pathogenesis in DbCM, a fatal fibrosis of the heart that occurs in both type 1 and type 2 diabetic patients, which leads to decreased contractility and decreased heart function, eventually resulting in overt heart failure. DbCM affects 17 – 24 percent of people with diabetes, or approximately 77 million patients worldwide.
ARISE-HF is a double-blind, placebo controlled, Phase 3 registrational trial expected to enroll approximately 675 type 2 diabetic patients with DbCM at high risk of progression to overt heart failure. ARISE-HF will assess AT-001’s ability to improve or prevent decline in exercise tolerance as measured by maximum amount of oxygen a person can utilize during intense exercise (peak VO2) over 15 months of treatment. The ARISE-HF trial will be conducted at approximately 70 centers in North America and Europe. Patients will be randomized 1:1:1 to either placebo, low dose AT-001 (1000mg), or high dose AT-001 (1500mg), taken twice daily. Additional supportive secondary and exploratory endpoints include percent of patients progressing to overt heart failure, quality of life metrics (modified KCCQ), echocardiographic measurements and cardiac stress biomarkers, including NTproBNP. At the conclusion of the core trial, patients may continue into a 12-month placebo-controlled extension study to assess potential impact on cardiovascular death and hospitalization.
“We are excited to announce the initiation of ARISE-HF, our pivotal trial in Diabetic Cardiomyopathy,” said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. “Diabetic Cardiomyopathy continues to be a growing issue for patients with diabetes, despite advancements in glucose control. Targeting aldose reductase with a potent and selective aldose reductase inhibitor presents an opportunity to potentially halt disease progression and prevent worsening of heart failure in DbCM patients. These patients have been left behind for far too long, and advancement of our program into this final phase of development is a major step forward.”
About Diabetic Cardiomyopathy
Diabetic Cardiomyopathy (DbCM) is a rapidly progressing degenerative disorder of the heart in patients with both type 1 and type 2 diabetes. There are no approved therapies for this fatal condition, which affects 17 – 24 percent of people with diabetes, or approximately 77 million patients worldwide. Hyperglycemia, a symptom that characterizes diabetes, triggers the enzyme Aldose Reductase to convert excess glucose into sorbitol and fructose, both of which can lead to cell death in the heart muscle. When this happens, the heart fibroses, or “hardens,” such that the organ is unable to circulate blood through the body effectively. Approximately 25 percent of patients with DbCM progress to overt heart failure or death within 1.5 years of diagnosis.
About AT-001
AT-001 is an investigational oral, novel, potent Aldose Reductase inhibitor in clinical development for the treatment of Diabetic Cardiomyopathy. AT-001 has been studied in a Phase 1/2 study in approximately 120 patients with type 2 diabetes, a subset of which had DbCM.
About Applied Therapeutics Inc.
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The company’s lead drug candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The company initiated a Phase 3 registrational study in DbCM in September 2019. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease, and initiated a Phase 1/2 clinical trial in June 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, expected to advance into a Phase 1 study in 2020.
SOURCE: Applied Therapeutics
Post Views: 426
NEW YORK, NY, USA I September 04, 2019 I Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the initiation of a Phase 3 registrational trial for AT-001, a novel, potent and selective aldose reductase inhibitor (ARI), in Diabetic Cardiomyopathy (DbCM). The study, called ARISE-HF, will investigate AT-001’s ability to improve or prevent the decline of functional capacity in patients with DbCM at high risk of progression to overt heart failure.
Aldose reductase (AR) activity has been implicated as a strong contributing factor to pathogenesis in DbCM, a fatal fibrosis of the heart that occurs in both type 1 and type 2 diabetic patients, which leads to decreased contractility and decreased heart function, eventually resulting in overt heart failure. DbCM affects 17 – 24 percent of people with diabetes, or approximately 77 million patients worldwide.
ARISE-HF is a double-blind, placebo controlled, Phase 3 registrational trial expected to enroll approximately 675 type 2 diabetic patients with DbCM at high risk of progression to overt heart failure. ARISE-HF will assess AT-001’s ability to improve or prevent decline in exercise tolerance as measured by maximum amount of oxygen a person can utilize during intense exercise (peak VO2) over 15 months of treatment. The ARISE-HF trial will be conducted at approximately 70 centers in North America and Europe. Patients will be randomized 1:1:1 to either placebo, low dose AT-001 (1000mg), or high dose AT-001 (1500mg), taken twice daily. Additional supportive secondary and exploratory endpoints include percent of patients progressing to overt heart failure, quality of life metrics (modified KCCQ), echocardiographic measurements and cardiac stress biomarkers, including NTproBNP. At the conclusion of the core trial, patients may continue into a 12-month placebo-controlled extension study to assess potential impact on cardiovascular death and hospitalization.
“We are excited to announce the initiation of ARISE-HF, our pivotal trial in Diabetic Cardiomyopathy,” said Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics. “Diabetic Cardiomyopathy continues to be a growing issue for patients with diabetes, despite advancements in glucose control. Targeting aldose reductase with a potent and selective aldose reductase inhibitor presents an opportunity to potentially halt disease progression and prevent worsening of heart failure in DbCM patients. These patients have been left behind for far too long, and advancement of our program into this final phase of development is a major step forward.”
About Diabetic Cardiomyopathy
Diabetic Cardiomyopathy (DbCM) is a rapidly progressing degenerative disorder of the heart in patients with both type 1 and type 2 diabetes. There are no approved therapies for this fatal condition, which affects 17 – 24 percent of people with diabetes, or approximately 77 million patients worldwide. Hyperglycemia, a symptom that characterizes diabetes, triggers the enzyme Aldose Reductase to convert excess glucose into sorbitol and fructose, both of which can lead to cell death in the heart muscle. When this happens, the heart fibroses, or “hardens,” such that the organ is unable to circulate blood through the body effectively. Approximately 25 percent of patients with DbCM progress to overt heart failure or death within 1.5 years of diagnosis.
About AT-001
AT-001 is an investigational oral, novel, potent Aldose Reductase inhibitor in clinical development for the treatment of Diabetic Cardiomyopathy. AT-001 has been studied in a Phase 1/2 study in approximately 120 patients with type 2 diabetes, a subset of which had DbCM.
About Applied Therapeutics Inc.
Applied Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The company’s lead drug candidate, AT-001, is a novel aldose reductase inhibitor (ARI) that is being developed for the treatment of Diabetic Cardiomyopathy, or DbCM, a fatal fibrosis of the heart. The company initiated a Phase 3 registrational study in DbCM in September 2019. Applied Therapeutics is also developing AT-007, a central nervous system penetrant ARI, for the treatment of Galactosemia, a rare pediatric metabolic disease, and initiated a Phase 1/2 clinical trial in June 2019. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of diabetic retinopathy, expected to advance into a Phase 1 study in 2020.
SOURCE: Applied Therapeutics
Post Views: 426
